ID   Gracie
AC   CVCL_L353
DR   GEO; GSM1974789
DR   Wikidata; Q54871668
RX   PubMed=21908323;
RX   PubMed=22916246;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=31175136;
RX   PubMed=36099278;
CC   Part of: FACC canine tumor cell line panel.
CC   Doubling time: 19.2 hours (PubMed=22916246); 19 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; 46802; SRGAP3; Simple; p.Val850fs (c.2548dupG); Zygosity=Heterozygous (PubMed=31175136).
CC   Omics: Deep exome analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Bone; UBERON=UBERON_0002481.
CC   Breed/subspecies: Golden Retriever; VBO=VBO_0200610.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 231,235
ST   Dog FHC2054: 156,172
ST   Dog FHC2079: 275,279
ST   Dog PEZ1: 115
ST   Dog PEZ3: 124,127
ST   Dog PEZ5: 111
ST   Dog PEZ6: 179,183
ST   Dog PEZ8: 240
ST   Dog PEZ12: 270,274
ST   Dog PEZ20: 180
DI   NCIt; C120045; Canine osteosarcoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 10-09-24; Version: 18
//
RX   PubMed=21908323; DOI=10.1177/1040638711408064;
RA   O'Donoghue L.E., Rivest J.P., Duval D.L.;
RT   "Polymerase chain reaction-based species verification and
RT   microsatellite analysis for canine cell line validation.";
RL   J. Vet. Diagn. Invest. 23:780-785(2011).
//
RX   PubMed=22916246; DOI=10.1371/journal.pone.0043355; PMCID=PMC3420908;
RA   Maeda J., Yurkon C.R., Fujisawa H., Kaneko M., Genet S.C.,
RA   Roybal E.J., Rota G.W., Saffer E.R., Rose B.J., Hanneman W.H.,
RA   Thamm D.H., Kato T.A.;
RT   "Genomic instability and telomere fusion of canine osteosarcoma
RT   cells.";
RL   PLoS ONE 7:E43355-E43355(2012).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:E0156689-E0156689(2016).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole-exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//
RX   PubMed=36099278; DOI=10.1371/journal.pone.0274383; PMCID=PMC9469990;
RA   Megquier K., Turner-Maier J., Morrill K., Li X., Johnson J.,
RA   Karlsson E.K., London C.A., Gardner H.L.;
RT   "The genomic landscape of canine osteosarcoma cell lines reveals
RT   conserved structural complexity and pathway alterations.";
RL   PLoS ONE 17:E0274383-E0274383(2022).
//